IIM
SMMT icon

INTECH Investment Management’s Summit Therapeutics SMMT Stock Holding History

INTECH Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-58,384
Closed -$1.13M – 2654
2025
Q1 		$1.13M Buy
58,384
+2,332
+4% +$46.8K 0.01% 1121
2024
Q4 		$1M Buy
56,052
+24,372
+77% +$472K 0.01% 1142
2024
Q3 		$694K Buy
+31,680
New +$443K 0.01% 1033

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

INTECH Investment Management's SMMT Position: Q2 2025 in Review

INTECH Investment Management sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 58,384 shares — an estimated $1.13M sold.

INTECH Investment Management first reported a position in SMMT in Q3 2024 and held it in 3 quarters. The position peaked at $1.13M in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • INTECH Investment Management reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 58,384 Summit Therapeutics shares in Q2 2025, an estimated $1.13M.
  • INTECH Investment Management first reported a position in Summit Therapeutics in Q3 2024 and held it in 3 quarters.
  • INTECH Investment Management's Summit Therapeutics position peaked at $1.13M in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.